Download PDF
Semin Liver Dis 2008; 28(1): 096-109
DOI: 10.1055/s-2008-1040324
© Thieme Medical Publishers

Artificial Liver Support Systems in the Management of Complications of Cirrhosis

Vanessa Stadlbauer1 , Nathan A. Davies1 , Sambit Sen1 , Rajiv Jalan1
  • 1Liver Failure Group, Institute of Hepatology, Division of Medicine, University College London, London, United Kingdom
Further Information

Publication History

Publication Date:
22 February 2008 (online)

    Permissions and Reprints

ABSTRACT

Acute-on-chronic liver failure (ACLF) is associated with multiorgan dysfunction requiring intensive care support and carries an exceptionally high risk of mortality. Decompensation of liver cirrhosis is triggered by different precipitating events but the final common pathway is hypothesized to be unregulated systemic inflammation. The concept of an artificial liver that may impact favorably upon the inflammatory response and provide liver function to prevent complications seems to be promising. This article aims to describe the currently available artificial and bioartificial systems and reviews their effect on different complications of cirrhosis, such as liver function and hepatic hemodynamics, renal function and systemic hemodynamics, hepatic encephalopathy, inflammation/infection, and coagulation. Due to the difficulties in studying large patient numbers with ACLF and the heterogeneity of this patient group, only limited data on survival are available. The currently available studies indicate that there is a survival benefit for artificial and bioartificial liver support in certain subgroups of patients; however, further studies are warranted. At present several studies in this field are under way. In this review several of the companies interested in the manufacture of the respective devices provide an up-to-date report of ongoing trials. In summary, artificial and bioartificial liver support are already playing important roles in the treatment of complications of ACLF. Better understanding of the pathophysiology of ACLF, further development of the current systems, and their evaluation in appropriately controlled clinical studies are necessary to translate their application to improvement in outcome of patients with ACLF.

KEYWORDS

Acute-on-chronic liver failure - complications of cirrhosis - artificial liver support - bioartificial liver support

REFERENCES

  • 1 World Health Organization .Projections of mortality and burden of disease to 2030. Available at: http://www.who.int/healthinfo/statistics/bodprojections2030/en/index.html
    Google Scholar
  • 2 Jalan R, Williams R. Acute-on-chronic liver failure: pathophysiological basis of therapeutic options.  Blood Purif. 2002;  20 252-261
    CrossrefPubMedGoogle Scholar
  • 3 Jalan R, Stadlbauer V, Sen S et al.. Natural history of acute decompensation of cirrhosis: the basis of the definition, prognosis and pathophysiology of acute on chronic liver failure.  Hepatology. 2006;  44 371A
    PubMedGoogle Scholar
  • 4 Stockmann H B, Ijzermans J N. Prospects for the temporary treatment of acute liver failure.  Eur J Gastroenterol Hepatol. 2002;  14 195-203
    CrossrefPubMedGoogle Scholar
  • 5 Shawcross D L, Davies N A, Williams R, Jalan R. Systemic inflammatory response exacerbates the neuropsychological effects of induced hyperammonemia in cirrhosis.  J Hepatol. 2004;  40 247-254
    CrossrefPubMedGoogle Scholar
  • 6 Shawcross D L, Wright G, Olde Damink S W, Jalan R. Role of ammonia and inflammation in minimal hepatic encephalopathy.  Metab Brain Dis. 2007;  22 125-138
    CrossrefPubMedGoogle Scholar
  • 7 Wright G, Davies N A, Shawcross D L et al.. Endotoxemia produces coma and brain swelling in bile duct-ligated rats.  Hepatology. 2007;  45 1517-1526
    CrossrefPubMedGoogle Scholar
  • 8 Mookerjee R P, Sen S, Davies N A, Hodges S J, Williams R, Jalan R. Tumour necrosis factor-alpha is an important mediator of portal and systemic haemodynamic derangements in alcoholic hepatitis.  Gut. 2003;  52 1182-1187
    CrossrefPubMedGoogle Scholar
  • 9 Mookerjee R P, Malaki M, Davies N A et al.. Increasing dimethylarginine levels are associated with adverse clinical outcome in severe alcoholic hepatitis.  Hepatology. 2007;  45 62-71
    CrossrefPubMedGoogle Scholar
  • 10 Mookerjee R P, Dalton R N, Davies N A et al.. Inflammation is an important determinant of levels of the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine (ADMA) in acute liver failure.  Liver Transpl. 2007;  13 400-405
    CrossrefPubMedGoogle Scholar
  • 11 Moreau R, Lebrec D. The use of vasoconstrictors in patients with cirrhosis: type 1 HRS and beyond.  Hepatology. 2006;  43 385-394
    CrossrefPubMedGoogle Scholar
  • 12 Genesca J, Gonzalez A, Segura R et al.. Interleukin-6, nitric oxide, and the clinical and hemodynamic alterations of patients with liver cirrhosis.  Am J Gastroenterol. 1999;  94 169-177
    CrossrefPubMedGoogle Scholar
  • 13 Kurtovic J, Boyle M, Bihari D, Riordan S M. Nitric-oxide-lowering effect of terlipressin in decompensated cirrhosis: comparison to the molecular adsorbent recirculating system and correlation with clinical status.  Eur J Gastroenterol Hepatol. 2004;  16 1335-1338
    CrossrefPubMedGoogle Scholar
  • 14 Sen S, Davies N A, Mookerjee R P et al.. Pathophysiological effects of albumin dialysis in acute-on-chronic liver failure: a randomized controlled study.  Liver Transpl. 2004;  10 1109-1119
    CrossrefPubMedGoogle Scholar
  • 15 Mookerjee R P, Stadlbauer V, Lidder S et al.. Neutrophil dysfunction in alcoholic hepatitis superimposed on cirrhosis is reversible and predicts outcome.  Hepatology. 2007;  46 831-840
    CrossrefPubMedGoogle Scholar
  • 16 Allen J W, Hassanein T, Bhatia S N. Advances in bioartificial liver devices.  Hepatology. 2001;  34 447-455
    CrossrefPubMedGoogle Scholar
  • 17 Strain A J, Neuberger J M. A bioartificial liver: state of the art.  Science. 2002;  295 1005-1009
    CrossrefPubMedGoogle Scholar
  • 18 Chamuleau R A, Deurholt T, Hoekstra R. Which are the right cells to be used in a bioartificial liver?.  Metab Brain Dis. 2005;  20 327-335
    CrossrefPubMedGoogle Scholar
  • 19 Di Nicuolo G, van de Kerkhove M P, Hoekstra R et al.. No evidence of in vitro and in vivo porcine endogenous retrovirus infection after plasmapheresis through the AMC-bioartificial liver.  Xenotransplantation. 2005;  12 286-292
    CrossrefPubMedGoogle Scholar
  • 20 Busse B, Gerlach J C. Bioreactors for hybrid liver support: historical aspects and novel designs.  Ann NY Acad Sci. 1999;  875 326-339
    PubMedGoogle Scholar
  • 21 Ash S R, Steczko J, Knab W R et al.. Push-pull sorbent-based pheresis and hemodiabsorption in the treatment of hepatic failure: preliminary results of a clinical trial with the BioLogic-DTPF System.  Ther Apher. 2000;  4 218-228
    PubMedGoogle Scholar
  • 22 Rozga J. Liver support technology: an update.  Xenotransplantation. 2006;  13 380-389
    CrossrefPubMedGoogle Scholar
  • 23 Jalan R, Kapoor D. Reversal of diuretic-induced hepatic encephalopathy with infusion of albumin but not colloid.  Clin Sci (Lond). 2004;  106 467-474
    PubMedGoogle Scholar
  • 24 Ortega R, Ginès P, Uriz J et al.. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study.  Hepatology. 2002;  36 941-948
    CrossrefPubMedGoogle Scholar
  • 25 Sort P, Navasa M, Arroyo V et al.. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis.  N Engl J Med. 1999;  341 403-409
    CrossrefPubMedGoogle Scholar
  • 26 Quinlan G J, Martin G S, Evans T W. Albumin: biochemical properties and therapeutic potential.  Hepatology. 2005;  41 1211-1219
    CrossrefPubMedGoogle Scholar
  • 27 Davies N A, Schnurr K, Sen S, Hodges S J, Matthes G, Jalan R. Serum albumin shows conformational, structural and functional abnormalities in cirrhotic patients, which worsens with severity of liver disease and are unaffected by albumin dialysis.  Hepatology. 2005;  42 A66
    PubMedGoogle Scholar
  • 28 Oettl K, Greilberger J, Stadlbauer V et al.. Redox state of serum albumin and carbonyl content of plasma proteins in advanced liver disease.  Free Radic Res. 2006;  40 S151
    PubMedGoogle Scholar
  • 29 Stange J, Ramlow W, Mitzner S, Schmidt R, Klinkmann H. Dialysis against a recycled albumin solution enables the removal of albumin-bound toxins.  Artif Organs. 1993;  17 809-813
    CrossrefPubMedGoogle Scholar
  • 30 Mitzner S R, Stange J, Klammt S et al.. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial.  Liver Transpl. 2000;  6 277-286
    CrossrefPubMedGoogle Scholar
  • 31 Heemann U, Treichel U, Loock J et al.. Albumin dialysis in cirrhosis with superimposed acute liver injury: a prospective, controlled study.  Hepatology. 2002;  36 949-958
    CrossrefPubMedGoogle Scholar
  • 32 Falkenhagen D, Strobl W, Vogt G et al.. Fractionated plasma separation and adsorption system: a novel system for blood purification to remove albumin bound substances.  Artif Organs. 1999;  23 81-86
    CrossrefPubMedGoogle Scholar
  • 33 Rifai K, Ernst T, Kretschmer U et al.. Prometheus: a new extracorporeal system for the treatment of liver failure.  J Hepatol. 2003;  39 984-990
    CrossrefPubMedGoogle Scholar
  • 34 Peszynski P, Klammt S, Peters E, Mitzner S, Stange J, Schmidt R. Albumin dialysis: single pass vs. recirculation (MARS).  Liver. 2002;  22(suppl 2) 40-42
    PubMedGoogle Scholar
  • 35 Sauer I M, Goetz M, Steffen I et al.. In vitro comparison of the molecular adsorbent recirculation system (MARS) and single-pass albumin dialysis (SPAD).  Hepatology. 2004;  39 1408-1414
    CrossrefPubMedGoogle Scholar
  • 36 Sauer I M, Zeilinger K, Obermayer N et al.. Primary human liver cells as source for modular extracorporeal liver support: a preliminary report.  Int J Artif Organs. 2002;  25 1001-1005
    PubMedGoogle Scholar
  • 37 Mazariegos G V, Patzer II J F, Lopez R C et al.. First clinical use of a novel bioartificial liver support system (BLSS).  Am J Transplant. 2002;  2 260-266
    CrossrefPubMedGoogle Scholar
  • 38 Dorrell C, Grompe M. Liver repair by intra- and extrahepatic progenitors.  Stem Cell Rev. 2005;  1 61-64
    CrossrefPubMedGoogle Scholar
  • 39 Oh S H, Hatch H M, Petersen B E. Hepatic oval “stem” cell in liver regeneration.  Semin Cell Dev Biol. 2002;  13 405-409
    CrossrefPubMedGoogle Scholar
  • 40 Hughes R D, Cochrane A M, Thomson A D, Murray-Lyon I M, Williams R. The cytotoxicity of plasma from patients with acute hepatic failure to isolated rabbit hepatocytes.  Br J Exp Pathol. 1976;  57 348-353
    PubMedGoogle Scholar
  • 41 Miwa Y, Ellis A J, Hughes R D, Langley P G, Wendon J A, Williams R. Effect of ELAD liver support on plasma HGF and TGF-beta 1 in acute liver failure.  Int J Artif Organs. 1996;  19 240-244
    PubMedGoogle Scholar
  • 42 Hughes R D, Nicolaou N, Langley P G, Ellis A J, Wendon J A, Williams R. Plasma cytokine levels and coagulation and complement activation during use of the extracorporeal liver assist device in acute liver failure.  Artif Organs. 1998;  22 854-858
    CrossrefPubMedGoogle Scholar
  • 43 Hurley J C, Tosolini F A, Louis W J. Quantitative Limulus lysate assay for endotoxin and the effect of plasma.  J Clin Pathol. 1991;  44 849-854
    CrossrefPubMedGoogle Scholar
  • 44 Abdala E, Baia C ES, Mies S et al.. Bacterial translocation during liver transplantation: a randomized trial comparing conventional with venovenous bypass vs. piggyback methods.  Liver Transpl. 2007;  13 488-496
    CrossrefPubMedGoogle Scholar
  • 45 Liu Q, Duan Z P, Huang C, Zhao C H. Evaluation of effect of hybrid bioartificial liver using end-stage liver disease model.  World J Gastroenterol. 2004;  10 1379-1381
    CrossrefPubMedGoogle Scholar
  • 46 Mitzner S, Loock J, Peszynski P et al.. Improvement in central nervous system functions during treatment of liver failure with albumin dialysis MARS: a review of clinical, biochemical, and electrophysiological data.  Metab Brain Dis. 2002;  17 463-475
    PubMedGoogle Scholar
  • 47 Jalan R, Sen S. Extracorporeal albumin dialysis for intoxication from protein-bound agents.  Crit Care Med. 2004;  32 1436-1437 , author reply 1437
    PubMedGoogle Scholar
  • 48 Sen S, Ytrebo L M, Rose C et al.. Albumin dialysis: a new therapeutic strategy for intoxication from protein-bound drugs.  Intensive Care Med. 2004;  30 496-501
    CrossrefPubMedGoogle Scholar
  • 49 Stange J, Mitzner S, Ramlow W, Gliesche T, Hickstein H, Schmidt R. A new procedure for the removal of protein-bound drugs and toxins.  ASAIO J. 1993;  39 M621-M625
    PubMedGoogle Scholar
  • 50 Stange J, Mitzner S. A carrier-mediated transport of toxins in a hybrid membrane: safety barrier between a patient's blood and a bioartificial liver.  Int J Artif Organs. 1996;  19 677-691
    PubMedGoogle Scholar
  • 51 Laleman W, Wilmer A, Evenepoel P et al.. Effect of the Molecular Adsorbent Recirculating System and Prometheus devices on systemic haemodynamics and vasoactive agents in patients with acute-on-chronic alcoholic liver failure.  Crit Care. 2006;  10 R108
    CrossrefPubMedGoogle Scholar
  • 52 Stadlbauer V, Krisper P, Aigner R et al.. Effect of extracorporeal liver support by MARS and Prometheus on serum cytokines in acute-on-chronic liver failure.  Crit Care. 2006;  10 R169
    CrossrefPubMedGoogle Scholar
  • 53 Sen S, Ratnaraj N, Davies N A et al.. Treatment of phenytoin toxicity by the molecular adsorbents recirculating system (MARS).  Epilepsia. 2003;  44 265-267
    CrossrefPubMedGoogle Scholar
  • 54 Stadlbauer V, Krisper P, Beuers U et al.. Removal of bile acids by two different extracorporeal liver support systems in acute-on-chronic liver failure.  ASAIO J. 2007;  53 187-193
    CrossrefPubMedGoogle Scholar
  • 55 Krisper P, Haditsch B, Stauber R et al.. In vivo quantification of liver dialysis: comparison of albumin dialysis and fractionated plasma separation.  J Hepatol. 2005;  43 451-457
    CrossrefPubMedGoogle Scholar
  • 56 Catalina M V, Barrio J, Anaya F et al.. Hepatic and systemic haemodynamic changes after MARS in patients with acute-on-chronic liver failure.  Liver Int. 2003;  23(suppl 3) 39-43
    PubMedGoogle Scholar
  • 57 Sen S, Mookerjee R P, Cheshire L M, Davies N A, Williams R, Jalan R. Albumin dialysis reduces portal pressure acutely in patients with severe alcoholic hepatitis.  J Hepatol. 2005;  43 142-148
    CrossrefPubMedGoogle Scholar
  • 58 Stange J, Mitzner S R, Risler T et al.. Molecular adsorbent recycling system (MARS): clinical results of a new membrane-based blood purification system for bioartificial liver support.  Artif Organs. 1999;  23 319-330
    PubMedGoogle Scholar
  • 59 Sorkine P, Ben Abraham R, Szold O et al.. Role of the molecular adsorbent recycling system (MARS) in the treatment of patients with acute exacerbation of chronic liver failure.  Crit Care Med. 2001;  29 1332-1336
    PubMedGoogle Scholar
  • 60 Rifai K, Ernst T, Kretschmer U et al.. The Prometheus device for extracorporeal support of combined liver and renal failure.  Blood Purif. 2005;  23 298-302
    CrossrefPubMedGoogle Scholar
  • 61 Henriksen J H, Moller S, Schifter S, Bendtsen F. Increased arterial compliance in decompensated cirrhosis.  J Hepatol. 1999;  31 712-718
    CrossrefPubMedGoogle Scholar
  • 62 Schrier R W, Arroyo V, Bernardi M, Epstein M, Henriksen J H, Rodés J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis.  Hepatology. 1988;  8 1151-1157
    CrossrefPubMedGoogle Scholar
  • 63 Mitzner S R, Klammt S, Peszynski P et al.. Improvement of multiple organ functions in hepatorenal syndrome during albumin dialysis with the molecular adsorbent recirculating system.  Ther Apher. 2001;  5 417-422
    CrossrefPubMedGoogle Scholar
  • 64 Schmidt L E, Wang L P, Hansen B A, Larsen F S. Systemic hemodynamic effects of treatment with the molecular adsorbents recirculating system in patients with hyperacute liver failure: a prospective controlled trial.  Liver Transpl. 2003;  9 290-297
    CrossrefPubMedGoogle Scholar
  • 65 Schmidt L E, Sorensen V R, Svendsen L B, Hansen B A, Larsen F S. Hemodynamic changes during a single treatment with the molecular adsorbents recirculating system in patients with acute-on-chronic liver failure.  Liver Transpl. 2001;  7 1034-1039
    CrossrefPubMedGoogle Scholar
  • 66 Fernández J, Navasa M, Garcia-Pagan J C et al.. Effect of intravenous albumin on systemic and hepatic hemodynamics and vasoactive neurohormonal systems in patients with cirrhosis and spontaneous bacterial peritonitis.  J Hepatol. 2004;  41 384-390
    CrossrefPubMedGoogle Scholar
  • 67 Stadlbauer V, Wright G AK, Banaji M et al.. Relationship between activation of the sympathetic nervous system and renal blood flow autoregulation in cirrhosis.  Gastroenterology. 2007;  , October 29 (Epub ahead of print)
    PubMedGoogle Scholar
  • 68 Jalan R, Mookerjee R P, Sen S, Redhead D N, Hayes P C, Williams R. Effect of TIPSS, terlipression, anti-TNF and paracentesis on renal blood flow autoregulation: new insights into the pathophysiological basis of renal dysfunction in cirrhosis.  Hepatology. 2004;  40 A1091
    PubMedGoogle Scholar
  • 69 Hassanein T I, Tofteng F, Brown Jr R S et al.. Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis.  Hepatology. 2007;  46 1853-1862
    CrossrefPubMedGoogle Scholar
  • 70 Sen S, Rose C, Ytrebo L M et al.. Effect of albumin dialysis on intracranial pressure increase in pigs with acute liver failure: a randomized study.  Crit Care Med. 2006;  34 158-164
    CrossrefPubMedGoogle Scholar
  • 71 Hiroma T, Nakamura T, Tamura M, Kaneko T, Komiyama A. Continuous venovenous hemodiafiltration in neonatal onset hyperammonemia.  Am J Perinatol. 2002;  19 221-224
    Article in Thieme ConnectPubMedGoogle Scholar
  • 72 Cordoba J, Blei A T, Mujais S. Determinants of ammonia clearance by hemodialysis.  Artif Organs. 1996;  20 800-803
    CrossrefPubMedGoogle Scholar
  • 73 Opolon P, Rapin J R, Huguet C et al.. Hepatic failure coma (HFC) treated by polyacrylonitrile membrane (PAN) hemodialysis (HD).  Trans Am Soc Artif Intern Organs. 1976;  22 701-710
    PubMedGoogle Scholar
  • 74 Kiley J E, Welch H F, Pender J C, Welch C S. Removal of blood ammonia by hemodialysis.  Proc Soc Exp Biol Med. 1956;  91 489-490
    PubMedGoogle Scholar
  • 75 Schmidt L E, Svendsen L B, Sorensen V R, Hansen B A, Larsen F S. Cerebral blood flow velocity increases during a single treatment with the Molecular Adsorbents Recirculating System in patients with acute on chronic liver failure.  Liver Transpl. 2001;  7 709-712
    CrossrefPubMedGoogle Scholar
  • 76 Liu J, Kjaergard L L, Als-Nielsen B, Gluud C. Artificial and bioartificial support systems for liver failure: a Cochrane Hepato-Biliary Group Protocol.  Liver. 2002;  22 433-438
    PubMedGoogle Scholar
  • 77 Samuel D, Ichai P, Feray C et al.. Neurological improvement during bioartificial liver sessions in patients with acute liver failure awaiting transplantation.  Transplantation. 2002;  73 257-264
    PubMedGoogle Scholar
  • 78 Demetriou A A, Brown Jr R S, Busuttil R W et al.. Prospective, randomized, multicenter, controlled trial of a bioartificial liver in treating acute liver failure.  Ann Surg. 2004;  239 660-667 discussion 667-70
    CrossrefPubMedGoogle Scholar
  • 79 Sen S, Williams R, Jalan R. The pathophysiological basis of acute-on-chronic liver failure.  Liver. 2002;  22(suppl 2) 5-13
    PubMedGoogle Scholar
  • 80 Rifai K, Ernst T, Kretschmer U, Haller H, Manns M P, Fliser D. Removal selectivity of Prometheus: a new extracorporeal liver support device.  World J Gastroenterol. 2006;  12 940-944
    PubMedGoogle Scholar
  • 81 Doria C, Marino I R. Bacteremia using the molecular adsorbent recirculating system in patients bridged to liver transplantation.  Exp Clin Transplant. 2005;  3 289-292
    PubMedGoogle Scholar
  • 82 Rifai K, Manns M P. Review article: clinical experience with Prometheus.  Ther Apher Dial. 2006;  10 132-137
    CrossrefPubMedGoogle Scholar
  • 83 Doria C, Mandala L, Smith J D et al.. Thromboelastography used to assess coagulation during treatment with molecular adsorbent recirculating system.  Clin Transplant. 2004;  18 365-371
    CrossrefPubMedGoogle Scholar
  • 84 Bachli E B, Schuepbach R A, Maggiorini M, Stocker R, Mullhaupt B, Renner E L. Artificial liver support with the Molecular Adsorbent Recirculating System: activation of coagulation and bleeding complications.  Liver Int. 2007;  27 475-484
    CrossrefPubMedGoogle Scholar
  • 85 Faybik P, Bacher A, Kozek-Langenecker S A et al.. Molecular adsorbent recirculating system and hemostasis in patients at high risk of bleeding: an observational study.  Crit Care. 2006;  10 R24
    CrossrefPubMedGoogle Scholar
  • 86 Pedersen R A, Kim W R, Sen S et al.. Is there really no life on MARS?.  Hepatology. 2004;  40 LB13
    PubMedGoogle Scholar
  • 87 Chen S C, Hewitt W R, Watanabe F D et al.. Clinical experience with a porcine hepatocyte-based liver support system.  Int J Artif Organs. 1996;  19 664-669
    PubMedGoogle Scholar
  • 88 Watanabe F D, Mullon C J, Hewitt W R et al.. Clinical experience with a bioartificial liver in the treatment of severe liver failure: a phase I clinical trial.  Ann Surg. 1997;  225 484-491 discussion 491-494
    CrossrefPubMedGoogle Scholar
  • 89 van de Kerkhove M P, Di Florio E, Scuderi V et al.. Phase I clinical trial with the AMC-bioartificial liver.  Int J Artif Organs. 2002;  25 950-959
    PubMedGoogle Scholar
  • 90 Neuzil D F, Rozga J, Moscioni A D et al.. Use of a novel bioartificial liver in a patient with acute liver insufficiency.  Surgery. 1993;  113 340-343
    PubMedGoogle Scholar
  • 91 Ellis A J, Hughes R D, Nicholl D et al.. Temporary extracorporeal liver support for severe acute alcoholic hepatitis using the BioLogic-DT.  Int J Artif Organs. 1999;  22 27-34
    PubMedGoogle Scholar
  • 92 Sauer I M, Kardassis D, Zeillinger K et al.. Clinical extracorporeal hybrid liver support: phase I study with primary porcine liver cells.  Xenotransplantation. 2003;  10 460-469
    CrossrefPubMedGoogle Scholar
  • 93 Khuroo M S, Farahat K L. Molecular adsorbent recirculating system for acute and acute-on-chronic liver failure: a meta-analysis.  Liver Transpl. 2004;  10 1099-1106
    CrossrefPubMedGoogle Scholar
  • 94 El Banayosy A, Kizner L, Schueler V, Bergmeier S, Cobaugh D, Koerfer R. First use of the Molecular Adsorbent Recirculating System technique on patients with hypoxic liver failure after cardiogenic shock.  ASAIO J. 2004;  50 332-337
    PubMedGoogle Scholar
  • 95 Chen S, Zhang L, Shi Y, Yang X, Wang M. Molecular Adsorbent Recirculating System: clinical experience in patients with liver failure based on hepatitis B in China.  Liver. 2002;  22(suppl 2) 48-51
    PubMedGoogle Scholar
  • 96 Hessel F P, Mitzner S R, Rief J, Guellstorff B, Steiner S, Wasem J. Economic evaluation and 1-year survival analysis of MARS in patients with alcoholic liver disease.  Liver Int. 2003;  23(suppl 3) 66-72
    PubMedGoogle Scholar
  • 97 Stange J. Meta-analysis in albumin dialysis: are we really ready for it?.  Liver Transpl. 2004;  10 1107-1108
    CrossrefPubMedGoogle Scholar
  • 98 Camus C, Lavoue S, Gacouin A et al.. Molecular adsorbent recirculating system dialysis in patients with acute liver failure who are assessed for liver transplantation.  Intensive Care Med. 2006;  32 1817-1825
    CrossrefPubMedGoogle Scholar
  • 99 Stange J, Hassanein T, Lynch P et al.. Short-term survival of patients with severe intractable hepatic encephalopathy: the role of albumin dialysis.  Hepatology. 2005;  42 285A
    PubMedGoogle Scholar
  • 100 Evenepoel P, Laleman W, Wilmer A et al.. Detoxifying capacity and kinetics of Prometheus: a new extracorporeal system for the treatment of liver failure.  Blood Purif. 2005;  23 349-358
    CrossrefPubMedGoogle Scholar
  • 101 Liu J P, Gluud L L, Als-Nielsen B, Gluud C. Artificial and bioartificial support systems for liver failure.  Cochrane Database Syst Rev. 2004;  CD003628
    PubMedGoogle Scholar
  • 102 Mareels G, Poyck P P, Eloot S, Chamuleau R A, Verdonck P R. Three-dimensional numerical modeling and computational fluid dynamics simulations to analyze and improve oxygen availability in the AMC bioartificial liver.  Ann Biomed Eng. 2006;  34 1729-1744
    CrossrefPubMedGoogle Scholar
  • 103 Poyck P P, Hoekstra R, Chhatta A et al.. Time-related analysis of metabolic liver functions, cellular morphology, and gene expression of hepatocytes cultured in the bioartificial liver of the Academic Medical Center in Amsterdam (AMC-BAL).  Tissue Eng. 2007;  13 1235-1246
    CrossrefPubMedGoogle Scholar
  • 104 Dhawan A, Mitry R R, Hughes R D. Hepatocyte transplantation for metabolic disorders: experience at King's College hospital and review of literature.  Acta Gastroenterol Belg. 2005;  68 457-460
    PubMedGoogle Scholar
  • 105 Aleem Khan A, Parveen N, Habeeb M A, Habibullah C M. Journey from hepatocyte transplantation to hepatic stem cells: a novel treatment strategy for liver diseases.  Indian J Med Res. 2006;  123 601-614
    PubMedGoogle Scholar
  • 106 Jalan R, Sen S, Williams R. Prospects for extracorporeal liver support.  Gut. 2004;  53 890-898
    CrossrefPubMedGoogle Scholar
  • 107 Sugio S, Kashima A, Mochizuki S, Noda M, Kobayashi K. Crystal structure of human serum albumin at 2.5 A resolution.  Protein Eng. 1999;  12 439-446
    CrossrefPubMedGoogle Scholar
  • 108 Curry S, Brick P, Franks N P. Fatty acid binding to human serum albumin: new insights from crystallographic studies.  Biochim Biophys Acta. 1999;  1441 131-140
    PubMedGoogle Scholar

Rajiv JalanM.D. 

The Institute of Hepatology, Division of Medicine, University College London

69-75 Chenies Mews, London WC1E 6HX, United Kingdom

Email: r.jalan@ucl.ac.uk